klisemfg Chapter 362 The three-year period has come to an end...
Chapter 362 The three-year period has come to an end...
……
"The treatment effect is acceptable and it does have a therapeutic effect on patients."
"Judging from the first week of treatment, the condition is indeed under control, which is consistent with the situation."
"There were no problems with the first month of treatment, and there were no problems with the first three months either. But I remember that there was an unexpected death during the clinical trial of Elsilan. Was that really an accident?"
Chen Xuan continued to analyze every possibility.
This anti-cancer drug, Elsilan, is actually a drug specifically used to treat breast cancer.
Past clinical trials have shown that long-term use of this drug can indeed control breast cancer.
It is indeed a very important drug that can control breast cancer without surgery, providing a better option for breast cancer treatment.
Most people would not want to have surgery if it is possible to avoid it.
Judging from the first two phases of clinical trials, there were no problems with the volunteers participating in the clinical trials, but there were also cases of death.
After investigation, it was confirmed that these deaths were caused by the volunteers' own illnesses and had nothing to do with the Alshiran anti-cancer drug.
At first, Chen Xuan did not doubt these deaths. Judging from the autopsy report, Elsilan's anti-cancer drugs could indeed be quickly ruled out, and such accidents had occurred in clinical trials.
After all, accidental death is normal, especially when the patient's physical condition is relatively poor, it is more likely to happen accidentally, and other diseases are more likely to occur.
But now, after repeated analysis, he suddenly discovered that what he originally thought was just an ordinary death was most likely not an accidental death, but was most likely caused by Elshilan.
It was just that it was not discovered at first and was mistakenly believed to be an accidental death caused by the patient's own illness and had nothing to do with the Alsilan anti-cancer drug.
But Chen Xuan no longer thinks so, because these deaths are too strange and it is difficult to determine whether they are real accidents.
Judging from the death cases, it is indeed difficult to link them to the anti-cancer drug Alciran, such as stroke, abnormal cardiac disease, vascular rupture, acute embolism, and aortic dissection.
The causes of death were so diverse that it was difficult to link them together.
If these deaths all have the same cause, it can be said that they are sequelae caused by the Elsilan anti-cancer drug.
But the cause of death for each person is different, so it is difficult to link them together.
It is no wonder that both the United States and Thailand believe that it was an accidental death and had nothing to do with the Elsilan anti-cancer drug.
Pfizer also made the same judgment, and other pharmaceutical companies also had no doubt about this. If they really thought there was a problem, it would have been exposed long ago and it would not have been kept secret.
In addition, these clinical trials were all conducted in Thailand, and the people who died were all poor people in Thailand. It is normal that they had diseases that were not discovered, and not many people would pay attention to the poor in Thailand.
Therefore, even though these deaths occurred, they did not cause much stir in the end, not to mention that it was proven that they had nothing to do with the Elsheran anti-cancer drug.
But now, when Chen Xuan looked through these death cases again, he made some unusual discoveries. He suspected that these deaths were caused by the Elshiran anti-cancer drug.
Although anti-cancer drugs can cause a variety of different diseases, which makes everyone's symptoms different, they also lead to various causes of death.
Of course, this is just his personal speculation after analyzing a large number of reports. He can only say that there is such a possibility, but it is difficult to say whether it is true.
But the more he analyzed the data, the more certain he became of this possibility, and it gradually became clear in his mind.
"I know, I finally know."
"I see!"
After analyzing the final result, Chen Xuan couldn't help but exclaim.
This result was indeed horrifying, and it finally made him understand why he hadn't been able to simulate it before.
It turned out that it was not his speculation, nor was there a problem with humans or the medical simulator, but that the test time was not enough.
"Bala, bala, bala..."
"Bala, bala, bala..."
At this moment, the machine suddenly sounded a rapid alarm.
This made Chen Xuan hurried over, because the alarm sound represented a simulated error.
The reason why an error is reported is that an abnormality is found, so a reminder is given in the form of an error.
When he saw the test results of the machine, he couldn't help but feel surprised, and then he was delighted.
Because this error data proved his previous speculation, he did not make any analysis errors, and everything was verified.
There are indeed problems with the Elsilan anti-cancer drug, and they are very serious.
The reason why the clinical trial data was modified is probably because Elshelan's team discovered this problem during the clinical trial.
This problem is likely to lead to the failure of the entire project, turning the priceless anti-cancer drug into a worthless waste drug, which is why it is covered up.
This hidden danger is most likely to be discovered during the Phase III clinical trial, and may only be known to the founder and a few core personnel, so it can be covered up.
If the disease is discovered early in phase I or II clinical trials, it would be impossible to proceed to phase III clinical trials.
They are absolutely unwilling to let all their previous efforts go to waste if things get to this point, especially when faced with a sky-high acquisition price, which makes this team choose to take risks.
When Chen Xuan thought of this, everything became clear.
Judging from the simulation results of humans and medical simulators, the Elsilan anti-cancer drug does have therapeutic effects.
The treatment effect in the first week and the first month was very good. It could temporarily control the breast cancer condition and prevent it from worsening, and even make the patients feel much more relieved.
This can be seen from the simulation results, which are no different from the clinical trials provided by Elshelan.
But after the third month of this simulation,
Chen Xuan discovered something wrong, but it was so subtle that it was usually not noticeable.
This abnormality will not gradually become apparent until half a year after taking the medicine, but it is difficult to discover this problem without a comprehensive examination.
After a year, this situation will gradually lead to serious consequences, such as sudden death from various diseases.
After three years of taking the drug, the mortality rate can be as high as 50%, which is much higher than the mortality rate of breast cancer itself.
In other words, if you do not take this medicine, you are less likely to die. However, long-term use of this medicine for more than three years can lead to a mortality rate of up to 50%.
The reason why the human and medical simulators sounded the alarm is that after three years of simulated medication, a large number of test templates died, with a mortality rate as high as 50%.
Of course, the current mortality rate of Elsilan anti-cancer drugs is not so shocking.
But it’s not because humans and medical simulators make mistakes in their simulations, nor is it because the real situation is better.
This is because so far, no one has taken the anti-cancer drug Elshelan normally for more than three years, and the longest time is just over a year.
The Phase III clinical trial of the Alsiran anti-cancer drug has only been going on for a few months.
However, the first two phases of clinical trials were relatively conservative, and the dosage of drugs used was relatively small. Even if there were problems, it would take a longer time for them to break out.
……